Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief scientific officer Dr Valentino Parravicini speaks to Proactive ahead of the Q1 2023 start of a new phase 1 trial for its lead compound, OCT461201. The study will target pain relief in those suffering from chemotherapy-induced peripheral neuropathy (CIPN) and irritable bowel syndrome (IBS).
Parravicini says that the new trial is "very positive" for the company. Back in August the company temporarily delayed a different first phase program in order to extend the group’s funding runway through to the end of 2023.
The results from the OCT461201 trial are expected to be published in April.